A phase II trial of personalized peptide vaccination for rare cancer or primary unknown cancer patients
Phase 2
- Conditions
- Rare cancer or primary unknown cancer
- Registration Number
- JPRN-UMIN000014855
- Lead Sponsor
- Kurume University Cancer Vaccine Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
Not provided
Exclusion Criteria
The following patients must be excluded: 1) Patients with severe symptoms (active and severe infectious disease, circulatory disease, respiratory disease, kidney disease, immunodeficiency and disturbance of coagulation). 2)Patients with the past history of severe allergic reactions. 3)(Female) Patients who are pregnancy,lactation and hope the graviditas. (male) Patient who do not agree prevebt pregnancy. 4)Patients who are judged inappropriate for entry to this clinical trial by doctor in charge.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method